⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics to Present at September Investor Conferences
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
globenewswire.com
CADL
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
globenewswire.com
CADL